Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Jiangxi Lihuo Biotechnology is a high-tech enterprise specializing in the development of rapid molecular diagnostic technologies. The company is centered around its proprietary Enzymatic Recombinase Amplification (ERA) platform, which enables highly sensitive and specific nucleic acid detection under isothermal conditions. This technology bypasses the need for complex thermal cycling equipment, making it ideal for point-of-care testing (POCT) in diverse environments. Lihuo Biotech's product portfolio spans human clinical diagnostics, veterinary health, and food safety testing, with a particular focus on infectious disease pathogens. By providing efficient and portable diagnostic solutions, the company supports rapid clinical decision-making and public health surveillance.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Jiangxi Lihuo Biotechnology.